Home » Newsletters » BioWorld Science

BioWorld Science

May 17, 1996

View Archived Issues

Pfizer claims analgesic bradykinin antagonists

Kappa-opioid agonists reported by Pfizer

Allergan claims retinoid-like compounds for dermatologic indications

ALA PDT results outstanding in patients with precancerous actinic keratoses

Takeda reports oral cephem antibacterials

Nippon Shoji to collaborate on nisin development in Pacific rim countries

Triazole antifungals reported by Tanabe

IDEC receives NIAID grant to develop MAbs for RSV

CMV NeutraGAM development update

Interferon Sciences reacquires U.S. and Canadian marketing rights for interferon product

HNK20 moves to phase III

HMR reports anti-HIV guanine derivative

Toho University reports anti-HIV zinc complex dimers

FDA okays second Cell Genesys AIDS gene therapy trial

Lexirin cleared to enter phase I

HIV fusin described in Science by NIAID researchers

UNAIDS initiates clinical program to evaluate Advantage 24 in STD transmission

COX-2 inhibitors claimed by Searle

Novel antiarthritics claimed by Procter & Gamble

British Biotech reveals metalloproteinase inhibitors

SmithKline Beecham's C-DART approach to rheumatoid arthritis

IMP dehydrogenase inhibitor synthesized at Roche Bioscience

Vical, Pasteur Merieux Connaught expand naked DNA vaccine collaboration

SKB and MicroCarb to collaborate on bacterial vaccines

New finding may help in overcoming bacterial resistance

Platinum complexes claimed by Nippon Kayaku

Supplemental NDA filed for Novantrone in U.S.

Human Genome Sciences claims chemokine beta-9 polypeptides and their antagonists

Promising clinical data for GVAX reported at scientific meeting

U.S. NDA filed for bropirimine

Genentech completes investment in IDEC ahead of schedule

Patent coverage obtained for Immune Response's cell therapy for B cell lymphoma

Mitsui Toatsu claims antitumor trifluorothymidine derivatives

SmithKline Beecham claims hemoregulatory agents

BioChem Therapeutic will codevelop VX-710 in Canada

Dorzolamide approved for marketing in Canada

Pharmos, Bausch & Lomb expand Lotemax agreement

SnET2 enters phase I/II for AMD indication

Anti-VEGF oligonucleotides inhibit retinal neovascularization in preclinical model

Creative Biomolecules, Stryker extend OP-1 agreement

FO-2546F: ACAT inhibitor from Albophoma yamanashiensis

Positive preliminary results announced for CholestaGel phase IIa study

rhIL-11 reduces need for platelet transfusions in chemotherapy recipients

Rockefeller reports new lead in the search for a treatment for cocaine addiction

Cocaine vaccine created by ImmuLogic

AMDL signs distribution agreement for DR-70

Sero-Strip HIV-1/2 100% specific and sensitive in Thai study

HIV Antigen EIA introduced outside U.S.

Sonus, Abbott sign strategic alliance agreement covering EchoGen Emulsion

Kit for glaucoma diagnosis in development at InSite Vision

Paroxetine approved for new indication

NIH scientists report ligands for alpha5-containing GABA-A receptors

Sertindole clinical trial results reported at APA meeting

Pfizer claims 5-HT1 agonists and antagonists for CNS disorders

5-HT1D antagonists disclosed by SmithKline Beecham

Scios to copromote venlafaxine with Wyeth-Ayerst

Ketoconazole: Potential treatment for depression?

Gensia, Pfizer to collaborate on ARA-based analgesics

Neuroprotective compounds target of new research agreement

Symbollon, Oclassen to codevelop dermatology products

ArQule's AMAP system receives patent coverage

Three-way collaboration in cardiovascular field announced

Xytronyx in-licenses LSAI technology

Canadian health authorities commission LifeTECH labs

Allergan calls off merger discussions with Pharmacia & Upjohn

Hafslund Nycomed demerger approved at AGM

Receptagen demerger on the table at AGM

SB-204269 in phase I for epilepsy

GP-3269 on track for clinical testing

Sankyo claims allosteric muscarinic effectors for AD

Increased platelet aggregation in AD patients

Valproate effective in dementia patients

NMDA antagonists reported by Pfizer

Seven new uses for raloxifene appear in patent literature

SB-238592: Antiinflammatory neuroprotectant in clinical phase

SB-221420 in development for stroke

Memantine to be tested in AIDS-related dementia, painful peripheral neuropathies

Pentoxifylline claimed for treating cold symptoms

Byk Gulden reports PDE IV inhibitors for asthma, dermatoses

PDE IV inhibitor SB-207499 in phase II

Takeda claims NK1 ligands for respiratory indications

NK1/NK2 antagonist MDL-105212: Potential antiasthmatic

SKB's anti-IL-5 MAb in preclinical testing for asthma

Pseudostat clinical results in bronchiectasis

Endothelin antagonists reported by Shionogi

New angiotensin II antagonist presented by Bayer at German pharmacology meeting

Shionogi and BMS to collaborate on irbesartan

Levcromakalim submitted for Japanese regulatory approval

FK-409 claimed as portal hypertension Rx

Merck & Co. claims class III antiarrhythmics

Fujisawa isolates cGMP PDE inhibitor from Pseudomonas

Lilly reports agents for septic shock

Teijin claims anticoagulant peptides

Active-site thrombin inhibitors reported by BMS

Argatroban enters phase III for HIT, HITTS

Fibrinogen antagonist from natrual source reported by Takeda

SKB discloses fibrinogen and vitronectin antagonists in patent literature

Hokuriku TxA2 antagonist selected for evaluation

NovoSeven Spanish introduction imminent

Disappointing results attained in Recordati/SKB BPH trial

Schering-Plough adenosine A1 receptor ligand described for renal failure

Zaprinast claimed for treatment of renal failure

RenaGel results announced at Harvard seminar

Yamanouchi claims antidiabetic agents

RPR, Novo Nordisk form global HRT alliance

Akzo Nobel claims contraceptive vaccines

Myotrophin up for advisory committee review

AmBisome approved in India

Ribonucleotide reductase inhibitor 3-AP in development at Vion

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...